Alector develops therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. ALEC reports earnings on Thu, Nov 5, 2026. In the past 30 days there were 2 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 14 | HC Wainwright & Co. | Maintained | Buy | |
| Oct 6 | Morgan Stanley | Maintained | Sell |
Seasonality
How ALEC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in ALEC in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALEC is in one of them and how their past ALEC trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ALEC in an article yet. Here's the latest on the wider market.
About Alector
Alector is a biotechnology company that develops treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. Its drug candidates aim to remove harmful proteins, replace missing ones, or restore normal cell function. The company also builds a proprietary technology designed to help drugs reach the brain, and it partners with drugmakers such as GSK on some programs. Based in South San Francisco, California, Alector is still testing its candidates in clinical studies.
- Headquarters
- South San Francisco, CA
- Founded
- 2013
- Website
- alector.com ↗